FOLFOX-4 regimen as first-line chemotherapy in elderly patients with advanced gastric cancer: A safety study

Journal of Chemotherapy

Volumn 19, Issue 1, 2007, Pages 85-89

  Nardi, M ^a   Azzarello, D ^a   Maisano, Roberto ^a,b   Del Medico, P ^a   Giannicola, R ^a   Raffaele, M ^a   Zavettieri, M ^a   Costarella, S ^a   Falzea, A ^a  

^a BIANCHI MELACRINO MORELLI HOSPITAL   (Italy)

^b NONE   (Italy)

Author keywords

Advanced gastric cancer; Elderly patients; Oxaliplatin

Indexed keywords

FLUOROURACIL; FOLINIC ACID; OXALIPLATIN;

ADVANCED CANCER; AGED; ALLERGY; ALOPECIA; ANEMIA; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CLINICAL ARTICLE; CONJUNCTIVITIS; CONTROLLED STUDY; DIARRHEA; DRUG ACTIVITY; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HUMAN; HYPESTHESIA; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PARESTHESIA; PATIENT COMPLIANCE; SENSORY NEUROPATHY; STOMACH CANCER; STOMATITIS; TREATMENT RESPONSE; VOMITING;

EID: 33846953183     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2007.19.1.85     Document Type: Article

References (11)

1. Ho D: Epidemiologic studies in gastric cancer, in Ho D (ed). Gastric Cancer. New York, NY, Churchill Livingstone, 1988: 1-25.
2. Kohne CH, Wils JA, Wilke HJ. Developments in the treatment of gastric cancer in Europe. Oncology (Huntingt) 2000; 14: 22-25.
3. Webb A, Cunningham D, Scarffe JH, et al. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol 1997; 15: 261-267.
4. Ajani JA, Van Cutsem E, Moiseyenko V, et al. Docetaxel (D), cisplatin, 5-fluorouracil compare to cisplatin (C) and 5-fluorouracil (F) for chemotherapy-naive patients with metastatic or locally recurrent, unresectable gastric carcinoma (MGC): Interim results of a randomized phase III trial (V325). Proc Am Soc Clin Oncol 2005; 23: abstr 4002.
5. Louvet C, Andre T, Tigaud JM et al. Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients. J Clin Oncol 2002; 20: 4543-4548.
6. Al-Batran SE, Amaca A, Hegewisch-Becke S et al: Phase II Trial of Biweekly Infusional Fluorouracil, Folinic Acid, and Oxaliplatin in Patients With Advanced Gastric Cancer. J Clin Oncol 2004; 22: 658-663.
7. Chao Y, Yeh KH, Chang CJ et al. Phase II study of weekly oxaliplatin and 24-h infusion of high-dose 5-fluorouracil and folinic acid in the treatment of advanced gastric cancer. Br J Cancer 2004; 91: 453-458.
8. De Vita F, Orditura M, Matano E et al. A phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients. Br J Cancer 2005; 92: 1644-1649.
9. Lordick F, Lorenzen S, Stollfuss J et al. Phase II study of weekly oxaliplatin plus infusional fluorouracil and folinic acid (FUFOX regimen) as first-line treatment in metastatic gastric cancer. Br J Cancer 2005; 93: 190-194.
10. Therasse P. Measuring the clinical response. What does it mean? Eur J Cancer 2002; 38,18:17-23.
11. th edn.), Brckle-Bust JC, Tallis RC, Fillit HM (Eds), Churcill Livingstone, Edinburgh, 1992: 26-608.